Drug ID:Drug102
Drug Name:Ferrous fumarate
CID:6433164
DrugBank ID:DB14491
Modality:Small Molecule
Groups:NULL
US Approved:YES
Other Approved:YES
Identifier: NCT05581420, , NCT05456932, , NCT06321887,
Molecular Formula:C4H2FeO4
Molecular Weight:169.9 g/mol
Isomeric SMILES:C(=C/C(=O)[O-])\\C(=O)[O-].[Fe+2]
Synonyms:Ferrous fumarate; 141-01-5; Ercoferro; Ferrofume; Hemoton; Toleron; Tolferain; Tolifer; Cpiron; Fumar
Phase 0: 1
Phase 1: 5
Phase 2: 7
Phase 3: 15
Phase 4: 18
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt870 6433164 Ferrous Fumarate 7037 TFRC Homo sapiens (human) 16564538 None
dt871 6433164 Ferrous Fumarate 54583 EGLN1 Homo sapiens (human) 16649251 None
dt872 6433164 Ferrous Fumarate 55869 HDAC8 Homo sapiens (human) 16681389 None
dt873 6433164 Ferrous Fumarate 51327 AHSP Homo sapiens (human) 16901899 None
dt874 6433164 Ferrous Fumarate 3040 HBA2 Homo sapiens (human) 16901899 None
dt875 6433164 Ferrous Fumarate 2395 FXN Homo sapiens (human) 16911956 None
dt876 6433164 Ferrous Fumarate 2495 FTH1 Homo sapiens (human) 17070541 None
dt877 6433164 Ferrous Fumarate 2237 FEN1 Homo sapiens (human) 20622253 None
dt878 6433164 Ferrous Fumarate 79661 NEIL1 Homo sapiens (human) 20622253 None
dt879 6433164 Ferrous Fumarate 252969 NEIL2 Homo sapiens (human) 20622253 None

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05581420 Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy. NA UNKNOWN Leiden University Medical Center Inflammatory Bowel Diseases DRUG: Ferrous fumarate|DRUG: MonoFer Details
NCT05456932 Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease PHASE4 UNKNOWN Leiden University Medical Center Inflammatory Bowel Diseases|Iron-deficiency|Iron … DRUG: Intravenous iron|DRUG: Ferric maltol|DRUG: … Details
EUCTR2018-002982-20-GB A Pilot Study to assess the efficacy and safety of reduced dose oral iron in the treatment of iron deficiency anaemia in inflammatory bowel disease patients - Efficacy and safety of low dose oral iron for anaemia in IBD (CAESAR) PHASE4 Authorised Royal Liverpool University Hospital Iron deficiency anaemia in inflammatory bowel dis… Trade Name: Ferrous Fumarate SyrupProduct Name: F… Details
NCT06321887 EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD PHASE3 UNKNOWN Liverpool University Hospitals NHS Foundation Trust Inflammatory Bowel Disease|Iron Deficiency Anemia DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammat…

PMID: 36563900
Year: 2023
Relationship Type: Treatment Score: 9.5

OBJECTIVE: To determine whether intravenous (IV) or oral iron suppletion is superior in improving physical fitness in anemic children with inflammato…

View Details
Oral ferrous fumarate or intravenous iron sucrose for patients with inflammator…

PMID: 16165718
Year: 2005
Relationship Type: Treatment Score: 6.1

BACKGROUND & AIMS: Growth hormone (GH) is used as therapy for inflammatory bowel disease (IBD), but the specific effects on intestine are unknown. T…

View Details